Skip to main content
. Author manuscript; available in PMC: 2018 Sep 15.
Published in final edited form as: Toxicol Appl Pharmacol. 2017 Apr 14;331:24–32. doi: 10.1016/j.taap.2017.04.016

Fig. 7. Acquired apoptosis resistance in Cr(VI)-transformed BEAS-2B cells.

Fig. 7

(A) Both BEAS-2B and Cr(VI)-transformed cells were treated with different concentrations of Cr(VI) for 24 hours. The whole cell lysates were collected to examine expressions of Bcl-2 and cleaved PARP (c-PARP) by immunoblot analysis. (B) Apoptosis was measured using FITC-conjugated Annexin V/PI staining by flow cytometry. Both BEAS-2B and Cr(VI)-transformed cells were seeded into 6-well culture plates (1×105cells/well). The cells were treated with different concentrations of Cr(VI). After 24 hours, 5 μL of fluorescein isothiocyanate (FITC)-labeled PI solution (10 μg/mL) was added into the cells. The percentage of apoptotic cells was measured using flow cytometry. Data are mean±SE (n=6). * indicates a p < 0.05, compared to normal BEAS-2B cells. BEAS-2B-Cr; Cr(VI)-transformed BEAS-2B cells.